Q-omics provides the consensus-scored CCNL1 profile across patient tissues and cancer cell-line models. CCNL1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CCNL1 is differentially expressed in 11, with the highest sampling consensus in BRCA. Additionally, CCNL1 protein abundance shows 19,653 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, BRCA, and LSCC as cancer lineages where CCNL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCNL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCNL1 survival associations across molecular data types. CCNL1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCNL1 RNA expression–survival associations across cancer types. High CCNL1 expression shows unfavorable associations in ACC, KIRC, UVM and LGG, but favorable associations in BLCA and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CCNL1 RNA expression.
This table summarizes CCNL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in BRCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CCNL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCNL1 shows lower tumor expression in BRCA, LUAD, THCA and KICH and higher tumor expression in COAD and KIRC. The BRCA box plot shows higher CCNL1 RNA expression in normal versus tumor tissue (log2 FC = −0.879, t-test p < 0.001).
This table shows molecular features associated with CCNL1 in patient tissues and cancer cell lines. In patient samples, CCNL1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCNL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SOFT_TISSUE.
